Martin Schostak MD, PhD
@martin-schostak.bsky.social
Professor of Urology, Berlin, Germany. Urologic Cancer Surgeon and urologic oncologist
Head of German Focal Treatment Experts
Head of https://logicuro.com
Head of German Focal Treatment Experts
Head of https://logicuro.com
Reposted by Martin Schostak MD, PhD
Congrats, Shilpa Gupta, for oral ASCO 2025 Abstract on mUC Bladder Cancer - Neeraj Agarwal
@neerajagarwal.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/shilpa-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASCO2025 #Abstract #BladderCancer #mUC
@neerajagarwal.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/shilpa-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASCO2025 #Abstract #BladderCancer #mUC
Neeraj Agarwal: Congrats Shilpa Gupta for oral ASCO 2025 Abstract on mUC Bladder Cancer - OncoDaily
Neeraj Agarwal: Congrats Shilpa Gupta for oral ASCO 2025 Abstract on mUC Bladder Cancer / Alexandra Drakaki, Begoña Valderrama, Blanca Homet Moreno, cancer,
oncodaily.com
May 27, 2025 at 2:47 PM
Congrats, Shilpa Gupta, for oral ASCO 2025 Abstract on mUC Bladder Cancer - Neeraj Agarwal
@neerajagarwal.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/shilpa-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASCO2025 #Abstract #BladderCancer #mUC
@neerajagarwal.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/shilpa-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASCO2025 #Abstract #BladderCancer #mUC
Reposted by Martin Schostak MD, PhD
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial
jamanetwork.com/journals/jam...
These findings suggest that microultrasonography could serve as an alternative to MRI for prostate cancer diagnosis.
#ProstateCancer
jamanetwork.com/journals/jam...
These findings suggest that microultrasonography could serve as an alternative to MRI for prostate cancer diagnosis.
#ProstateCancer
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis
This randomized, noninferiority trial of biopsy-naive men compares the detection of Gleason Grade Group ≥2 prostate cancer using microultrasonography-guided and MRI fusion-guided biopsy.
jamanetwork.com
March 26, 2025 at 4:07 PM
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial
jamanetwork.com/journals/jam...
These findings suggest that microultrasonography could serve as an alternative to MRI for prostate cancer diagnosis.
#ProstateCancer
jamanetwork.com/journals/jam...
These findings suggest that microultrasonography could serve as an alternative to MRI for prostate cancer diagnosis.
#ProstateCancer
Proud to be one of the investigators: #MicroUS noninferior to MRI fusion for csPCa (46.1% vs 42.6%)! No MRI, slightly better results. 802 pts, 8 countries. Just presented #EAU25 and published in #JAMA. #ProstateCancer #biopsy @axelmerseburger.bsky.social
March 24, 2025 at 11:38 AM
Proud to be one of the investigators: #MicroUS noninferior to MRI fusion for csPCa (46.1% vs 42.6%)! No MRI, slightly better results. 802 pts, 8 countries. Just presented #EAU25 and published in #JAMA. #ProstateCancer #biopsy @axelmerseburger.bsky.social
LATP hits harder: +5.7% GG≥2 vs TRUS (p=0.031)! Fewer infections, slightly more pain & embarrassment. No abx needed. Costlier, slower—but sharper. #TRANSLATEtrial #ProstateCancer #LATP #TRUS #EAU25 #LancetOncology @axelmerseburger.bsky.social
March 24, 2025 at 11:36 AM
LATP hits harder: +5.7% GG≥2 vs TRUS (p=0.031)! Fewer infections, slightly more pain & embarrassment. No abx needed. Costlier, slower—but sharper. #TRANSLATEtrial #ProstateCancer #LATP #TRUS #EAU25 #LancetOncology @axelmerseburger.bsky.social
The very first post-ASCO GU meeting this year ! @yukselurun.bsky.social
February 16, 2025 at 10:41 PM
The very first post-ASCO GU meeting this year ! @yukselurun.bsky.social
Reposted by Martin Schostak MD, PhD
@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25
February 14, 2025 at 5:07 PM
@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25
🚀 Excited for #ASCOGU25! Looking forward to groundbreaking insights and game-changers once again! 🔬 Can't wait to see what’s ahead. 🎯 Stay tuned! #UroOncology #GameChanger
@axelmerseburger.bsky.social
@axelmerseburger.bsky.social
February 8, 2025 at 2:38 PM
🚀 Excited for #ASCOGU25! Looking forward to groundbreaking insights and game-changers once again! 🔬 Can't wait to see what’s ahead. 🎯 Stay tuned! #UroOncology #GameChanger
@axelmerseburger.bsky.social
@axelmerseburger.bsky.social
🔥 #TestisCancer highlight from #ASCOGU!
📌 Abstract 618 – Final results of the #COTRIMS trial: Retroperitoneal lymphadenectomy in metastatic #Seminoma.
Important data for #GermCellTumors! What’s your take?
📌 Abstract 618 – Final results of the #COTRIMS trial: Retroperitoneal lymphadenectomy in metastatic #Seminoma.
Important data for #GermCellTumors! What’s your take?
February 8, 2025 at 9:30 AM
🔥 #TestisCancer highlight from #ASCOGU!
📌 Abstract 618 – Final results of the #COTRIMS trial: Retroperitoneal lymphadenectomy in metastatic #Seminoma.
Important data for #GermCellTumors! What’s your take?
📌 Abstract 618 – Final results of the #COTRIMS trial: Retroperitoneal lymphadenectomy in metastatic #Seminoma.
Important data for #GermCellTumors! What’s your take?
🚀 Key #UrothelialCancer abstracts from #ASCOGU!
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
February 8, 2025 at 9:29 AM
🚀 Key #UrothelialCancer abstracts from #ASCOGU!
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
🔥 Exciting #ProstateCancer Abstracts from #ASCOGU:
📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial.
📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer.
📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.
📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial.
📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer.
📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.
February 8, 2025 at 9:28 AM
🔥 Exciting #ProstateCancer Abstracts from #ASCOGU:
📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial.
📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer.
📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.
📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial.
📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer.
📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.
Reposted by Martin Schostak MD, PhD
Patients receiving a personalized cancer vaccine #PCV for #renalcellcarcinoma remained cancer-free after 40 months, according to a phase 1 study led by Dr. David Braun and @danafarber.bsky.social colleagues published today in
#Nature.
yalecancercenter.org/news-article...
#Nature.
yalecancercenter.org/news-article...
Personalized therapeutic vaccine ‘steers’ the immune system to fight kidney cancer
Vaccines are on the cutting edge of cancer therapy research as a possible treatment option for the future. The trial led by Yale Cancer Center (YCC) principal
yalecancercenter.org
February 5, 2025 at 7:05 PM
Patients receiving a personalized cancer vaccine #PCV for #renalcellcarcinoma remained cancer-free after 40 months, according to a phase 1 study led by Dr. David Braun and @danafarber.bsky.social colleagues published today in
#Nature.
yalecancercenter.org/news-article...
#Nature.
yalecancercenter.org/news-article...
Reposted by Martin Schostak MD, PhD
Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer
www.nature.com/articles/s41...
This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab
www.nature.com/articles/s41...
www.nature.com/articles/s41...
This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab
www.nature.com/articles/s41...
February 5, 2025 at 7:18 PM
Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer
www.nature.com/articles/s41...
This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab
www.nature.com/articles/s41...
www.nature.com/articles/s41...
This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab
www.nature.com/articles/s41...
February 2, 2025 at 3:58 PM
February 2, 2025 at 2:44 PM
Reposted by Martin Schostak MD, PhD
🔵1 in 3 men experience PSA persistence or relapse within 10 years post-radical prostatectomy.
🔵Early relapse (<2 years) = higher PCa death risk (8.5%) vs. late relapse (>5 years, 1.4%).
🔵Life expectancy and relapse timing guide treatment. #ProstateCancer #Oncology
@oncoalert.bsky.social
🔵Early relapse (<2 years) = higher PCa death risk (8.5%) vs. late relapse (>5 years, 1.4%).
🔵Life expectancy and relapse timing guide treatment. #ProstateCancer #Oncology
@oncoalert.bsky.social
January 20, 2025 at 7:13 PM
🔵1 in 3 men experience PSA persistence or relapse within 10 years post-radical prostatectomy.
🔵Early relapse (<2 years) = higher PCa death risk (8.5%) vs. late relapse (>5 years, 1.4%).
🔵Life expectancy and relapse timing guide treatment. #ProstateCancer #Oncology
@oncoalert.bsky.social
🔵Early relapse (<2 years) = higher PCa death risk (8.5%) vs. late relapse (>5 years, 1.4%).
🔵Life expectancy and relapse timing guide treatment. #ProstateCancer #Oncology
@oncoalert.bsky.social
Reposted by Martin Schostak MD, PhD
🧬💊2024 FDA approvals highlight cancer as a priority: 15 (30%) novel drugs, including the 11th PD1/PDL1 blocker.
🎯 Our mission is clear: ensure the right treatment is available and accessible to every patient. Equity in care is non-negotiable.
@oncoalert.bsky.social @oncbrothers.bsky.social
🎯 Our mission is clear: ensure the right treatment is available and accessible to every patient. Equity in care is non-negotiable.
@oncoalert.bsky.social @oncbrothers.bsky.social
January 4, 2025 at 3:54 PM
🧬💊2024 FDA approvals highlight cancer as a priority: 15 (30%) novel drugs, including the 11th PD1/PDL1 blocker.
🎯 Our mission is clear: ensure the right treatment is available and accessible to every patient. Equity in care is non-negotiable.
@oncoalert.bsky.social @oncbrothers.bsky.social
🎯 Our mission is clear: ensure the right treatment is available and accessible to every patient. Equity in care is non-negotiable.
@oncoalert.bsky.social @oncbrothers.bsky.social
Reposted by Martin Schostak MD, PhD
FDA Approvals for GU Cancers in 2024: Advancing Treatment Options!
#GUOncology #Cancer #FDA #Oncology @oncoalert.bsky.social @uroweb.bsky.social @oncbrothers.bsky.social
@drchoueiri.bsky.social @viveksubbiah.bsky.social
@erplimackmd.bsky.social
@charlesryanmd.bsky.social @gu-cast.bsky.social
#GUOncology #Cancer #FDA #Oncology @oncoalert.bsky.social @uroweb.bsky.social @oncbrothers.bsky.social
@drchoueiri.bsky.social @viveksubbiah.bsky.social
@erplimackmd.bsky.social
@charlesryanmd.bsky.social @gu-cast.bsky.social
December 30, 2024 at 5:36 PM
FDA Approvals for GU Cancers in 2024: Advancing Treatment Options!
#GUOncology #Cancer #FDA #Oncology @oncoalert.bsky.social @uroweb.bsky.social @oncbrothers.bsky.social
@drchoueiri.bsky.social @viveksubbiah.bsky.social
@erplimackmd.bsky.social
@charlesryanmd.bsky.social @gu-cast.bsky.social
#GUOncology #Cancer #FDA #Oncology @oncoalert.bsky.social @uroweb.bsky.social @oncbrothers.bsky.social
@drchoueiri.bsky.social @viveksubbiah.bsky.social
@erplimackmd.bsky.social
@charlesryanmd.bsky.social @gu-cast.bsky.social
Reposted by Martin Schostak MD, PhD
THE best presentation of study figures ever! 😆
"We presented scaled versions of this puzzle to both people and ants (Fig. 1 A and B)."
per Proceedings of the National Academy of Sciences @pnas.org
www.pnas.org/doi/10.1073/...
"We presented scaled versions of this puzzle to both people and ants (Fig. 1 A and B)."
per Proceedings of the National Academy of Sciences @pnas.org
www.pnas.org/doi/10.1073/...
December 27, 2024 at 7:59 PM
THE best presentation of study figures ever! 😆
"We presented scaled versions of this puzzle to both people and ants (Fig. 1 A and B)."
per Proceedings of the National Academy of Sciences @pnas.org
www.pnas.org/doi/10.1073/...
"We presented scaled versions of this puzzle to both people and ants (Fig. 1 A and B)."
per Proceedings of the National Academy of Sciences @pnas.org
www.pnas.org/doi/10.1073/...
Reposted by Martin Schostak MD, PhD
“FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors”.
Great news for patients, more convenient treatments, and less time- and resource-consuming schedules. www.onclive.com/view/fda-app...
Great news for patients, more convenient treatments, and less time- and resource-consuming schedules. www.onclive.com/view/fda-app...
FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.
www.onclive.com
December 27, 2024 at 8:29 PM
“FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors”.
Great news for patients, more convenient treatments, and less time- and resource-consuming schedules. www.onclive.com/view/fda-app...
Great news for patients, more convenient treatments, and less time- and resource-consuming schedules. www.onclive.com/view/fda-app...
Reposted by Martin Schostak MD, PhD
#Nectin4 in GU vs other malignancies
✅ Nectin4 is more prevalent in GU cancers than others
✅ still more data needed on the prognostic and predictive value
👉 Interested in more data on how prior treatment impacts Nectin4 + how this could impact treatment sequence @oncodaily.bsky.social #BladderCancer
✅ Nectin4 is more prevalent in GU cancers than others
✅ still more data needed on the prognostic and predictive value
👉 Interested in more data on how prior treatment impacts Nectin4 + how this could impact treatment sequence @oncodaily.bsky.social #BladderCancer
Nectin-4 Positivity in GU Malignancies - Emanuele Crupi
oncodaily.com/insight/eman...
#BladderCancer #Cancer #GUMalignancies #Health #JCOPrecisionOncology #OncoDaily #Oncology #Medicine
oncodaily.com/insight/eman...
#BladderCancer #Cancer #GUMalignancies #Health #JCOPrecisionOncology #OncoDaily #Oncology #Medicine
Emanuele Crupi: Nectin-4 Positivity in GU Malignancies - OncoDaily
Emanuele Crupi: Nectin-4 Positivity in GU Malignancies / Andrea Necchi, bladder cancer, cancer, Daniele Raggi, Emanuele Crupi, GU malignancies, JCO Precision
oncodaily.com
December 8, 2024 at 4:47 AM
#Nectin4 in GU vs other malignancies
✅ Nectin4 is more prevalent in GU cancers than others
✅ still more data needed on the prognostic and predictive value
👉 Interested in more data on how prior treatment impacts Nectin4 + how this could impact treatment sequence @oncodaily.bsky.social #BladderCancer
✅ Nectin4 is more prevalent in GU cancers than others
✅ still more data needed on the prognostic and predictive value
👉 Interested in more data on how prior treatment impacts Nectin4 + how this could impact treatment sequence @oncodaily.bsky.social #BladderCancer
Reposted by Martin Schostak MD, PhD
Adjuvant nivolumab continues to show significant benefits in MIUC. At 36.1 months, DFS & OS improved in ITT (DFS HR 0.71, OS HR 0.76) and PD-L1 ≥1% (DFS HR 0.52, OS HR 0.56). No new safety signals. #oncology #cancer @oncoalert.bsky.social
doi.org/10.1200/JCO....
doi.org/10.1200/JCO....
December 24, 2024 at 5:57 AM
Adjuvant nivolumab continues to show significant benefits in MIUC. At 36.1 months, DFS & OS improved in ITT (DFS HR 0.71, OS HR 0.76) and PD-L1 ≥1% (DFS HR 0.52, OS HR 0.56). No new safety signals. #oncology #cancer @oncoalert.bsky.social
doi.org/10.1200/JCO....
doi.org/10.1200/JCO....
Wieso ist der #X-Account des #Magdeburg-Attentäters mit fast 50.000 Followern nach über drei Tagen noch immer online? Wenn die #Plattform #X schon nicht agiert, vielleicht sogar, weil ihr Chef eine solche „Meinungsfreiheit“ unterstützt, warum tut das BKA oder das Innenministerium denn auch nichts?
December 23, 2024 at 10:38 PM
Wieso ist der #X-Account des #Magdeburg-Attentäters mit fast 50.000 Followern nach über drei Tagen noch immer online? Wenn die #Plattform #X schon nicht agiert, vielleicht sogar, weil ihr Chef eine solche „Meinungsfreiheit“ unterstützt, warum tut das BKA oder das Innenministerium denn auch nichts?
Reposted by Martin Schostak MD, PhD
Initial active surveillance and watchful waiting significantly increased for intermediate–risk prostate cancer between 2010 and 2020.
https://ja.ma/4042hPZ
https://ja.ma/4042hPZ
December 22, 2024 at 8:00 PM
Initial active surveillance and watchful waiting significantly increased for intermediate–risk prostate cancer between 2010 and 2020.
https://ja.ma/4042hPZ
https://ja.ma/4042hPZ
Reposted by Martin Schostak MD, PhD
ASCO – Applications are open for an interactive clinical research course with AIOM
@ascocancer.bsky.social
oncodaily.com/blog/asco-21...
#ASCO #Cancer #OncoDaily #Oncology #Medicine #Health
@ascocancer.bsky.social
oncodaily.com/blog/asco-21...
#ASCO #Cancer #OncoDaily #Oncology #Medicine #Health
ASCO - Applications are open for an interactive clinical research course with AIOM - OncoDaily
ASCO - Applications are open for an interactive clinical research course with AIOM / ASCO, cancer, OncoDaily, Oncology
oncodaily.com
December 22, 2024 at 5:01 PM
ASCO – Applications are open for an interactive clinical research course with AIOM
@ascocancer.bsky.social
oncodaily.com/blog/asco-21...
#ASCO #Cancer #OncoDaily #Oncology #Medicine #Health
@ascocancer.bsky.social
oncodaily.com/blog/asco-21...
#ASCO #Cancer #OncoDaily #Oncology #Medicine #Health
I am not only leaving the University of #Magdeburg but also #X
You can now find me here and at logicuro.com
You can now find me here and at logicuro.com
December 23, 2024 at 4:42 PM
I am not only leaving the University of #Magdeburg but also #X
You can now find me here and at logicuro.com
You can now find me here and at logicuro.com